Impact of host genetic polymorphisms on vaccine induced antibody response

Human Vaccines and Immunotherapeutics

Volumn 12, Issue 4, 2016, Pages 907-915

  Linnik, Janina E ^a,b,c   Egli, Adrian ^a,d  

^a UNIVERSITY OF BASEL   (Switzerland)

^b ETH ZURICH   (Switzerland)

^c SWISS INSTITUTE OF BIOINFORMATICS   (Switzerland)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

antibodies; genetic polymorphism; GWAS; immune response; individualized vaccination; Influenza; Measles; SNP; systems biology; vaccine

Indexed keywords

CD45 ANTIGEN; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 6; STAT PROTEIN; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 1; VACCINE; INFLUENZA VACCINE; MEASLES VACCINE; VIRUS ANTIBODY;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; ANTIBODY RESPONSE; CELL PROLIFERATION; DENDRITIC CELL; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; MOLECULAR INTERACTION; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; ANTIBODY PRODUCTION; BLOOD; GENE EXPRESSION; GENETICS; IMMUNOLOGY; INFLUENZA; MEASLES; MEASLES VIRUS; PERSONALIZED MEDICINE; SYSTEMS BIOLOGY; VACCINATION; VIROLOGY;

ANTIBODIES, VIRAL; ANTIBODY FORMATION; GENE EXPRESSION; HUMANS; IMMUNITY, HUMORAL; INFLUENZA VACCINES; INFLUENZA, HUMAN; MEASLES; MEASLES VACCINE; MEASLES VIRUS; POLYMORPHISM, SINGLE NUCLEOTIDE; PRECISION MEDICINE; SYSTEMS BIOLOGY; VACCINATION; VACCINES;

EID: 84961114771     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.1080/21645515.2015.1119345     Document Type: Review

References (100)

1. F.E.Andre, R.Booy, H.L.Bock, J.Clemens, S.K.Datta, T.J.John, B.W.Lee, S.Lolekha, H.Peltola, T.A.Ruff, et al. Vaccination greatly reduces disease, disability, death and inequity worldwide. Bull World Health Organ 2008; 86:140-6; PMID:18297169; http://dx.doi.org/10.2471/BLT.07.040089
2. D.C.Kaslow, S.Biernaux. RTS,S: Toward a first landmark on the Malaria Vaccine Technology Roadmap. Vaccine 2015; 33(52):7425-32
3. P.Mangtani, I.Abubakar, C.Ariti, R.Beynon, L.Pimpin, P.E.Fine, L.C.Rodrigues, P.G.Smith, M.Lipman, P.F.Whiting, et al. Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials. Clin Infect Dis 2014; 58:470-80; PMID:24336911; http://dx.doi.org/10.1093/cid/cit790
4. C.A.Siegrist, R.Aspinall. B-cell responses to vaccination at the extremes of age. Nat Rev Immunol 2009; 9:185-94; PMID:19240757; http://dx.doi.org/10.1038/nri2508
5. A.N.Faucette, B.L.Unger, B.Gonik, K.Chen. Maternal vaccination: moving the science forward. Hum Reprod Update 2015; 21:119-35; PMID:25015234; http://dx.doi.org/10.1093/humupd/dmu041
6. S.A.Smith, G.A.Poland, A.American Diabetes. Influenza and pneumococcal immunization in diabetes. Diabetes Care 2004; 27 Suppl 1:S111-113; PMID:14693944
7. L.B.Gelinck, Y.K.Teng, G.F.Rimmelzwaan, B.J.van den Bemt, F.P.Kroon, J.M.van Laar. Poor serological responses upon influenza vaccination in patients with rheumatoid arthritis treated with rituximab. Ann Rheum Dis 2007; 66:1402-3; PMID:17881666; http://dx.doi.org/10.1136/ard.2007.071878
8. S.van Assen, A.Holvast, C.A.Benne, M.D.Posthumus, M.A.van Leeuwen, A.E.Voskuyl, M.Blom, A.P.Risselada, A.de Haan, J.Westra, et al. Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum 2010; 62:75-81; PMID:20039396; http://dx.doi.org/10.1002/art.25033
9. O.Manuel, M.Pascual, K.Hoschler, S.Giulieri, D.Alves, K.Ellefsen, P.A.Bart, J.P.Venetz, T.Calandra, M.Cavassini. Humoral response to the influenza A H1N1/09 monovalent AS03-adjuvanted vaccine in immunocompromised patients. Clin Infect Dis 2011; 52:248-56; PMID:21288852; http://dx.doi.org/10.1093/cid/ciq104
10. K.M.Kunisaki, E.N.Janoff. Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infect Dis 2009; 9:493-504; PMID:19628174; http://dx.doi.org/10.1016/S1473-3099(09)70175-6
11. P.Ljungman. Vaccination of immunocompromised patients. Clin Microbiol Infect 2012; 18 Suppl 5:93-9; PMID:23051059; http://dx.doi.org/10.1111/j.1469-0691.2012.03971.x
12. T.Hagan, H.I.Nakaya, S.Subramaniam, B.Pulendran. Systems vaccinology: Enabling rational vaccine design with systems biological approaches. Vaccine 2015; 33(40):5294-301; PMID:25858860
13. R.N.Germain. Vaccines and the future of human immunology. Immunity 2010; 33:441-50; PMID:21029956; http://dx.doi.org/10.1016/j.immuni.2010.09.014
14. E.N.Fish. The X-files in immunity: sex-based differences predispose immune responses. Nat Rev Immunol 2008; 8:737-44; PMID:18728636; http://dx.doi.org/10.1038/nri2394
15. D.O'Shea, L.A.Widmer, J.Stelling, A.Egli. Changing face of vaccination in immunocompromised hosts. Curr Infect Dis Rep 2014; 16:420; PMID:24992978; http://dx.doi.org/10.1007/s11908-014-0420-2
16. A.Egli, D.Santer, K.Barakat, M.Zand, A.Levin, M.Vollmer, M.Weisser, N.Khanna, D.Kumar, L.Tyrrell, et al. Vaccine adjuvants–understanding molecular mechanisms to improve vaccines. Swiss Med Wkly 2014; 144:w13940; PMID:24844935
17. L.M.Franco, K.L.Bucasas, J.M.Wells, D.Nino, X.Wang, G.E.Zapata, N.Arden, A.Renwick, P.Yu, J.M.Quarles, et al. Integrative genomic analysis of the human immune response to influenza vaccination. Elife 2013; 2:e00299; PMID:23878721; http://dx.doi.org/10.7554/eLife.00299
18. P.L.Tan, R.M.Jacobson, G.A.Poland, S.J.Jacobsen, V.S.Pankratz. Twin studies of immunogenicity–determining the genetic contribution to vaccine failure. Vaccine 2001; 19:2434-9; PMID:11257374; http://dx.doi.org/10.1016/S0264-410X(00)00468-0
19. I.G.Ovsyannikova, I.H.Haralambieva, R.A.Vierkant, M.M.O'Byrne, R.M.Jacobson, G.A.Poland. The association of CD46, SLAM and CD209 cellular receptor gene SNPs with variations in measles vaccine-induced immune responses: a replication study and examination of novel polymorphisms. Hum Hered 2011; 72:206-23; PMID:22086389; http://dx.doi.org/10.1159/000331585
20. P.G.Ferreira, E.T.Dermitzakis. Immune response is a personal matter. Elife 2013; 2:e00899; PMID:23878727; http://dx.doi.org/10.7554/eLife.00899
21. B.Pulendran. Systems vaccinology: probing humanity's diverse immune systems with vaccines. Proc Natl Acad Sci U S A 2014; 111:12300-6; PMID:25136102; http://dx.doi.org/10.1073/pnas.1400476111
22. J.J.Nauta, W.E.Beyer, A.D.Osterhaus. On the relationship between mean antibody level, seroprotection and clinical protection from influenza. Biologicals 2009; 37:216-21; PMID:19268607; http://dx.doi.org/10.1016/j.biologicals.2009.02.002
23. T.Kawai, S.Akira. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 2010; 11:373-84; PMID:20404851; http://dx.doi.org/10.1038/ni.1863
24. K.Honda, T.Taniguchi. IRFs: master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors. Nat Rev Immunol 2006; 6:644-58; PMID:16932750; http://dx.doi.org/10.1038/nri1900
25. L.Chen, D.B.Flies. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol 2013; 13:227-42; PMID:23470321; http://dx.doi.org/10.1038/nri3405
26. M.H.Kaplan, U.Schindler, S.T.Smiley, M.J.Grusby. Stat6 is required for mediating responses to IL-4 and for development of Th2 cells. Immunity 1996; 4:313-9; PMID:8624821; http://dx.doi.org/10.1016/S1074-7613(00)80439-2
27. N.Mari, M.Hercor, S.Denanglaire, O.Leo, F.Andris. The capacity of Th2 lymphocytes to deliver B-cell help requires expression of the transcription factor STAT3. Eur J Immunol 2013; 43(6):1489-98; PMID:23504518
28. D.A.Randolph, G.Huang, C.J.Carruthers, L.E.Bromley, D.D.Chaplin. The role of CCR7 in TH1 and TH2 cell localization and delivery of B cell help in vivo. Science 1999; 286:2159-62; PMID:10591648; http://dx.doi.org/10.1126/science.286.5447.2159
29. H.MacLeod, L.M.Wetzler. T cell activation by TLRs: a role for TLRs in the adaptive immune response. Sci STKE 2007; 2007:pe48; PMID:17785715; http://dx.doi.org/10.1126/stke.4022007pe48
30. S.Tartey, K.Matsushita, T.Imamura, A.Wakabayashi, D.Ori, T.Mino, O.Takeuchi. Essential Function for the Nuclear Protein Akirin2 in B Cell Activation and Humoral Immune Responses. J Immunol 2015; 195:519-27; PMID:26041538; http://dx.doi.org/10.4049/jimmunol.1500373
31. R.Albert. Scale-free networks in cell biology. J Cell Sci 2005; 118:4947-57; PMID:16254242; http://dx.doi.org/10.1242/jcs.02714
32. H.W.Han, J.H.Ohn, J.Moon, J.H.Kim. Yin and Yang of disease genes and death genes between reciprocally scale-free biological networks. Nucleic Acids Res 2013; 41:9209-17; PMID:23935122; http://dx.doi.org/10.1093/nar/gkt683
33. A.Wagner. Robustness against mutations in genetic networks of yeast. Nat Genet 2000; 24:355-61; PMID:10742097; http://dx.doi.org/10.1038/74174
34. R.Albert, H.Jeong, A.L.Barabasi. Error and attack tolerance of complex networks. Nature 2000; 406:378-82; PMID:10935628; http://dx.doi.org/10.1038/35019019
35. J.Stelling, U.Sauer, Z.Szallasi, F.J.Doyle, 3rd, J.Doyle. Robustness of cellular functions. Cell 2004; 118:675-85; PMID:15369668; http://dx.doi.org/10.1016/j.cell.2004.09.008
36. H.Kitano. Biological robustness. Nat Rev Genet 2004; 5:826-37; PMID:15520792; http://dx.doi.org/10.1038/nrg1471
37. T.B.Lavoie, E.Kalie, S.Crisafulli-Cabatu, R.Abramovich, G.DiGioia, K.Moolchan, S.Pestka, G.Schreiber. Binding and activity of all human α interferon subtypes. Cytokine 2011; 56:282-9; PMID:21856167; http://dx.doi.org/10.1016/j.cyto.2011.07.019
38. A.A.Abdul-Sater, A.Majoros, C.R.Plumlee, S.Perry, A.D.Gu, C.Lee, S.Shresta, T.Decker, C.Schindler. Different STAT Transcription Complexes Drive Early and Delayed Responses to Type I IFNs. J Immunol 2015; 195:210-6; PMID:26019270; http://dx.doi.org/10.4049/jimmunol.1401139
39. U.A.Kohler, F.Bohm, F.Rolfs, M.Egger, T.Hornemann, M.Pasparakis, A.Weber, S.Werner. NF-kappaB/RelA and Nrf2 cooperate to maintain hepatocyte integrity and to prevent development of hepatocellular adenoma. J Hepatol 2016; 64(1):94-102; PMID:26348541.
40. S.Bank, P.Skytt Andersen, J.Burisch, N.Pedersen, S.Roug, J.Galsgaard, S.Ydegaard Turino, J.Broder Brodersen, S.Rashid, B.Kaiser Rasmussen, et al. Polymorphisms in the inflammatory pathway genes TLR2, TLR4, TLR9, LY96, NFKBIA, NFKB1, TNFA, TNFRSF1A, IL6R, IL10, IL23R, PTPN22, and PPARG are associated with susceptibility of inflammatory bowel disease in a Danish cohort. PLoS One 2014; 9:e98815; PMID:24971461; http://dx.doi.org/10.1371/journal.pone.0098815
41. S.C.Gough, M.J.Simmonds. The HLA Region and Autoimmune Disease: Associations and Mechanisms of Action. Curr Genomics 2007; 8:453-65; PMID:19412418; http://dx.doi.org/10.2174/138920207783591690
42. A.Smahi, G.Courtois, S.H.Rabia, R.Doffinger, C.Bodemer, A.Munnich, J.L.Casanova, A.Israël. The NF-kappaB signalling pathway in human diseases: from incontinentia pigmenti to ectodermal dysplasias and immune-deficiency syndromes. Hum Mol Genet 2002; 11:2371-5; PMID:12351572; http://dx.doi.org/10.1093/hmg/11.20.2371
43. P.F.Halloran. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004; 351:2715-29; PMID:15616206; http://dx.doi.org/10.1056/NEJMra033540
44. N.Scheinfeld. A comprehensive review and evaluation of the side effects of the tumor necrosis factor α blockers etanercept, infliximab and adalimumab. J Dermatolog Treat 2004; 15:280-94; PMID:15370396; http://dx.doi.org/10.1080/09546630410017275
45. R.Rappuoli, A.Aderem. A 2020 vision for vaccines against HIV, tuberculosis and malaria. Nature 2011; 473:463-9; PMID:21614073; http://dx.doi.org/10.1038/nature10124
46. P.Prachi, C.Donati, F.Masciopinto, R.Rappuoli, F.Bagnoli. Deep sequencing in pre- and clinical vaccine research. Public Health Genomics 2013; 16:62-8; PMID:23548719; http://dx.doi.org/10.1159/000345611
47. S.Buhler, A.Sanchez-Mazas. HLA DNA sequence variation among human populations: molecular signatures of demographic and selective events. PLoS One 2011; 6:e14643; PMID:21408106; http://dx.doi.org/10.1371/journal.pone.0014643
48. A.J.Brookes. The essence of SNPs. Gene 1999; 234:177-86; PMID:10395891; http://dx.doi.org/10.1016/S0378-1119(99)00219-X
49. M.W.Snyder, A.Adey, J.O.Kitzman, J.Shendure. Haplotype-resolved genome sequencing: experimental methods and applications. Nat Rev Genet 2015; 16:344-58; PMID:25948246; http://dx.doi.org/10.1038/nrg3903
50. M.J.Daly, J.D.Rioux, S.F.Schaffner, T.J.Hudson, E.S.Lander. High-resolution haplotype structure in the human genome. Nat Genet 2001; 29:229-32; PMID:11586305; http://dx.doi.org/10.1038/ng1001-229
51. S.Kim, A.Misra. SNP genotyping: technologies and biomedical applications. Annu Rev Biomed Eng 2007; 9:289-320; PMID:17391067; http://dx.doi.org/10.1146/annurev.bioeng.9.060906.152037
52. E.S.Lander, L.M.Linton, B.Birren, C.Nusbaum, M.C.Zody, J.Baldwin, K.Devon, K.Dewar, M.Doyle, W.FitzHugh, et al. Initial sequencing and analysis of the human genome. Nature 2001; 409:860-921; PMID:11237011; http://dx.doi.org/10.1038/35057062
53. R.Sachidanandam, D.Weissman, S.C.Schmidt, J.M.Kakol, L.D.Stein, G.Marth, S.Sherry, J.C.Mullikin, B.J.Mortimore, D.L.Willey, et al. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 2001; 409:928-33; PMID:11237013; http://dx.doi.org/10.1038/35057149
54. D.G.Wang, J.B.Fan, C.J.Siao, A.Berno, P.Young, R.Sapolsky, G.Ghandour, N.Perkins, E.Winchester, J.Spencer, et al. Large-scale identification, mapping, and genotyping of single-nucleotide polymorphisms in the human genome. Science 1998; 280:1077-82; PMID:9582121; http://dx.doi.org/10.1126/science.280.5366.1077
55. L.Musumeci, J.W.Arthur, F.S.Cheung, A.Hoque, S.Lippman, J.K.Reichardt. Single nucleotide differences (SNDs) in the dbSNP database may lead to errors in genotyping and haplotyping studies. Hum Mutat 2010; 31:67-73; PMID:19877174; http://dx.doi.org/10.1002/humu.21137
56. A.A.Mitchell, M.E.Zwick, A.Chakravarti, D.J.Cutler Discrepancies in dbSNP confirmation rates and allele frequency distributions from varying genotyping error rates and patterns. Bioinformatics 2004; 20:1022-32; PMID:14764571; http://dx.doi.org/10.1093/bioinformatics/bth034
57. International HapMap C, D.M.Altshuler, R.A.Gibbs, L.Peltonen, D.M.Altshuler, R.A.Gibbs, L.Peltonen, E.Dermitzakis, S.F.Schaffner, F.Yu, et al. Integrating common and rare genetic variation in diverse human populations. Nature 2010; 467:52-8; PMID:20811451; http://dx.doi.org/10.1038/nature09298
58. B.S.Shastry. SNPs: impact on gene function and phenotype. Methods Mol Biol 2009; 578:3-22; PMID:19768584; http://dx.doi.org/10.1007/978-1-60327-411-1_1
59. Y.H.Zhang, Y.Zhao, N.Li, Y.C.Peng, E.Giannoulatou, R.H.Jin, H.P.Yan, H.Wu, J.H.Liu, N.Liu, et al. Interferon-induced transmembrane protein-3 genetic variant rs12252-C is associated with severe influenza in Chinese individuals. Nat Commun 2013; 4:1418; PMID:23361009; http://dx.doi.org/10.1038/ncomms2433
60. Z.X.Dong, H.J.Zhou, X.G.Xiang, S.M.Guo, Y.Zhuang, G.D.Zhao, Q.Xie. IL28B genetic variations are associated with treatment response of patients with chronic hepatitis C in a Chinese Han population. J Dig Dis 2015; 16:90-7; PMID:25312023; http://dx.doi.org/10.1111/1751-2980.12202
61. C.Fernandez-Carrillo, M.Coto-Llerena, P.Gonzalez, G.Crespo, L.Mensa, N.Caro-Pérez, M.Gambato, M.Navasa, X.Forns, S.Pérez-del-Pulgar. IFNL4 polymorphism predicts response to hepatitis C treatment after liver transplantation. J Clin Virol 2014; 61:282-5; PMID:25130512; http://dx.doi.org/10.1016/j.jcv.2014.07.015
62. A.Egli, D.M.Santer, D.O'Shea, K.Barakat, M.Syedbasha, M.Vollmer, A.Baluch, R.Bhat, J.Groenendyk, M.A.Joyce, et al. IL-28B is a key regulator of B- and T-cell vaccine responses against influenza. PLoS Pathog 2014; 10:e1004556; PMID:25503988; http://dx.doi.org/10.1371/journal.ppat.1004556
63. H.M.Lazear, T.J.Nice, M.S.Diamond. Interferon-lambda: Immune Functions at Barrier Surfaces and Beyond. Immunity 2015; 43:15-28; PMID:26200010; http://dx.doi.org/10.1016/j.immuni.2015.07.001
64. A.Egli, M.D.Santer, D.O'Shea, D.L.Tyrrell, M.Houghton. The impact of the interferon-lambda family on the innate and adaptive immune response to viral infections. Emerg Infect Dis 2014;3(7):e51. http://dx.doi.org/10.1038/emi.2014.51
65. S.Chinnaswamy, S.Chatterjee, R.Boopathi, S.Mukherjee, S.Bhattacharjee, T.K.Kundu. A single nucleotide polymorphism associated with hepatitis C virus infections located in the distal region of the IL28B promoter influences NF-kappaB-mediated gene transcription. PLoS One 2013; 8:e75495; PMID:24116050; http://dx.doi.org/10.1371/journal.pone.0075495
66. J.Fischer, S.Bohm, M.Scholz, T.Muller, H.Witt, J.George, C.Sarrazin, S.Susser, E.Schott, V.Suppiah, et al. Combined effects of different interleukin-28B gene variants on the outcome of dual combination therapy in chronic hepatitis C virus type 1 infection. Hepatology 2012; 55:1700-10; PMID:22234924; http://dx.doi.org/10.1002/hep.25582
67. E.Aparicio, M.Parera, S.Franco, N.Perez-Alvarez, C.Tural, B.Clotet, M.A.Martínez. IL28B SNP rs8099917 is strongly associated with pegylated interferon-α and ribavirin therapy treatment failure in HCV/HIV-1 coinfected patients. PLoS One 2010; 5:e13771; PMID:21048934; http://dx.doi.org/10.1371/journal.pone.0013771
68. S.Resham, S.Manzoor, M.Imran, M.Saalim, S.Naseem, S.Azam. Interleukin- 28B: a prognostic marker in interferon based therapy of chronic HCV patients of the Pakistan with variable treatment response. APMIS 2015; 123(9):765-71
69. V.Suppiah, M.Moldovan, G.Ahlenstiel, T.Berg, M.Weltman, M.L.Abate, M.Bassendine, U.Spengler, G.J.Dore, E.Powell, et al. IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy. Nat Genet 2009; 41:1100-4; PMID:19749758; http://dx.doi.org/10.1038/ng.447
70. Y.Tanaka, N.Nishida, M.Sugiyama, M.Kurosaki, K.Matsuura, N.Sakamoto, M.Nakagawa, M.Korenaga, K.Hino, S.Hige, et al. Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41:1105-9; PMID:19749757; http://dx.doi.org/10.1038/ng.449
71. S.Bibert, A.Wojtowicz, P.Taffe, O.Manuel, E.Bernasconi, H.Furrer, H.F.Günthard, M.Hoffmann, L.Kaiser, M.Osthoff, et al. The IFNL3/4 DeltaG variant increases susceptibility to cytomegalovirus retinitis among HIV-infected patients. AIDS 2014; 28:1885-9; PMID:25259701; http://dx.doi.org/10.1097/QAD.0000000000000379
72. O.Manuel, A.Wojtowicz, S.Bibert, N.J.Mueller, C.van Delden, H.H.Hirsch, J.Steiger, M.Stern, A.Egli, C.Garzoni, et al. Influence of IFNL3/4 polymorphisms on the incidence of cytomegalovirus infection after solid-organ transplantation. J Infect Dis 2015; 211:906-14; PMID:25301956; http://dx.doi.org/10.1093/infdis/jiu557
73. I.H.Haralambieva, I.G.Ovsyannikova, B.J.Umlauf, R.A.Vierkant, V.Shane Pankratz, R.M.Jacobson, G.A.Poland. Genetic polymorphisms in host antiviral genes: associations with humoral and cellular immunity to measles vaccine. Vaccine 2011; 29:8988-97; PMID:21939710; http://dx.doi.org/10.1016/j.vaccine.2011.09.043
74. S.Srinivas, J.Dai, J.Eskdale, G.E.Gallagher, N.J.Megjugorac, G.Gallagher. Interferon-lambda1 (interleukin-29) preferentially down-regulates interleukin-13 over other T helper type 2 cytokine responses in vitro. Immunology 2008; 125:492-502; PMID:18547367; http://dx.doi.org/10.1111/j.1365-2567.2008.02862.x
75. W.J.Jordan, J.Eskdale, S.Srinivas, V.Pekarek, D.Kelner, M.Rodia, G.Gallagher. Human interferon lambda-1 (IFN-lambda1/IL-29) modulates the Th1/Th2 response. Genes Immun 2007; 8:254-61; PMID:17361203; http://dx.doi.org/10.1038/sj.gene.6364382
76. J.Dai, N.J.Megjugorac, G.E.Gallagher, R.Y.Yu, G.Gallagher. IFN-lambda1 (IL-29) inhibits GATA3 expression and suppresses Th2 responses in human naive and memory T cells. Blood 2009; 113:5829-38; PMID:19346497; http://dx.doi.org/10.1182/blood-2008-09-179507
77. O.Koltsida, M.Hausding, A.Stavropoulos, S.Koch, G.Tzelepis, C.Ubel, S.V.Kotenko, P.Sideras, H.A.Lehr, M.Tepe, et al. IL-28A (IFN-lambda2) modulates lung DC function to promote Th1 immune skewing and suppress allergic airway disease. EMBO Mol Med 2011; 3:348-61; PMID:21538995; http://dx.doi.org/10.1002/emmm.201100142
78. T.Steck, P.Albert, M.Weppler, W.Becker, H.Spingler, W.Würfel, I.von Hertwig. [The effect of an intrauterine device on passive sperm transport in the uterus and fallopian tube at the time of ovulation]. Gynakol Rundsch 1989; 29 Suppl 2:430-2; PMID:2613070; http://dx.doi.org/10.1159/000271144
79. C.M.Gelder, R.Lambkin, K.W.Hart, D.Fleming, O.M.Williams, M.Bunce, K.I.Welsh, S.E.Marshall, J.Oxford. Associations between human leukocyte antigens and nonresponsiveness to influenza vaccine. J Infect Dis 2002; 185:114-7; PMID:11756990; http://dx.doi.org/10.1086/338014
80. G.A.Poland, I.G.Ovsyannikova, R.M.Jacobson. Immunogenetics of seasonal influenza vaccine response. Vaccine 2008; 26 Suppl 4:D35-40; PMID:19230157; http://dx.doi.org/10.1016/j.vaccine.2008.07.065
81. B.J.Hennig, K.Fielding, J.Broxholme, M.Diatta, M.Mendy, C.Moore, A.J.Pollard, P.Rayco-Solon, G.Sirugo, M.A.van der Sande, et al. Host genetic factors and vaccine-induced immunity to hepatitis B virus infection. PLoS One 2008; 3:e1898; PMID:18365030; http://dx.doi.org/10.1371/journal.pone.0001898
82. I.G.Ovsyannikova, R.B.Kennedy, M.O'Byrne, R.M.Jacobson, V.S.Pankratz, G.A.Poland. Genome-wide association study of antibody response to smallpox vaccine. Vaccine 2012; 30:4182-9; PMID:22542470; http://dx.doi.org/10.1016/j.vaccine.2012.04.055
83. I.H.Haralambieva, I.G.Ovsyannikova, R.B.Kennedy, R.A.Vierkant, V.S.Pankratz, R.M.Jacobson, G.A.Poland. Associations between single nucleotide polymorphisms and haplotypes in cytokine and cytokine receptor genes and immunity to measles vaccination. Vaccine 2011; 29:7883-95; PMID:21875636; http://dx.doi.org/10.1016/j.vaccine.2011.08.083
84. R.B.Kennedy, I.G.Ovsyannikova, I.H.Haralambieva, N.D.Lambert, V.S.Pankratz, G.A.Poland. Genome-wide SNP associations with rubella-specific cytokine responses in measles-mumps-rubella vaccine recipients. Immunogenetics 2014; 66:493-9; PMID:24811271; http://dx.doi.org/10.1007/s00251-014-0776-3
85. I.H.Haralambieva, N.D.Lambert, I.G.Ovsyannikova, R.B.Kennedy, B.R.Larrabee, V.S.Pankratz, G.A.Poland. Associations between single nucleotide polymorphisms in cellular viral receptors and attachment factor-related genes and humoral immunity to rubella vaccination. PLoS One 2014; 9:e99997; PMID:24945853; http://dx.doi.org/10.1371/journal.pone.0099997
86. A.T.Hattersley, M.I.McCarthy. What makes a good genetic association study? Lancet 2005; 366:1315-23; PMID:16214603; http://dx.doi.org/10.1016/S0140-6736(05)67531-9
87. E.Png, A.Thalamuthu, R.T.Ong, H.Snippe, G.J.Boland, M.Seielstad. A genome-wide association study of hepatitis B vaccine response in an Indonesian population reveals multiple independent risk variants in the HLA region. Hum Mol Genet 2011; 20:3893-8; PMID:21764829; http://dx.doi.org/10.1093/hmg/ddr302
88. P.I.de Bakker, R.Yelensky, I.Pe'er, S.B.Gabriel, M.J.Daly, D.Altshuler. Efficiency and power in genetic association studies. Nat Genet 2005; 37:1217-23; PMID:16244653; http://dx.doi.org/10.1038/ng1669
89. E.P.Hong, J.W.Park. Sample size and statistical power calculation in genetic association studies. Genomics Inform 2012; 10:117-22; PMID:23105939; http://dx.doi.org/10.5808/GI.2012.10.2.117
90. C.C.Spencer, Z.Su, P.Donnelly, J.Marchini. Designing genome-wide association studies: sample size, power, imputation, and the choice of genotyping chip. PLoS Genet 2009; 5:e1000477; PMID:19492015; http://dx.doi.org/10.1371/journal.pgen.1000477
91. W.E.Beyer, A.M.Palache, G.Luchters, J.Nauta, A.D.Osterhaus Seroprotection rate, mean fold increase, seroconversion rate: which parameter adequately expresses seroresponse to influenza vaccination? Virus Res 2004; 103:125-32; PMID:15163500
92. M.C.King, J.H.Marks, J.B.Mandell, New York Breast Cancer Study G Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003; 302:643-6; PMID:14576434; http://dx.doi.org/10.1126/science.1088759
93. B.Weigelt, J.L.Peterse, L.J.van 't Veer. Breast cancer metastasis: markers and models. Nat Rev Cancer 2005; 5:591-602; PMID:16056258; http://dx.doi.org/10.1038/nrc1670
94. N.J.Van Eck, L.Waltman. Software survey: VOSviewer, a computer program for bibliometric mapping. Scientometrics 2010; 84:523-38; PMID:20585380; http://dx.doi.org/10.1007/s11192-009-0146-3
95. V.Becker, M.Schilling, J.Bachmann, U.Baumann, A.Raue, T.Maiwald, J.Timmer, U.Klingmüller. Covering a broad dynamic range: information processing at the erythropoietin receptor. Science 2010; 328:1404-8; PMID:20488988; http://dx.doi.org/10.1126/science.1184913
96. T.Maiwald, A.Schneider, H.Busch, S.Sahle, N.Gretz, T.S.Weiss, U.Kummer, U.Klingmüller. Combining theoretical analysis and experimental data generation reveals IRF9 as a crucial factor for accelerating interferon α-induced early antiviral signalling. FEBS J 2010; 277:4741-54; PMID:20964804; http://dx.doi.org/10.1111/j.1742-4658.2010.07880.x
97. B.N.Kholodenko. Cell-signalling dynamics in time and space. Nat Rev Mol Cell Biol 2006; 7:165-76; PMID:16482094; http://dx.doi.org/10.1038/nrm1838
98. P.Rangamani, R.Iyengar. Modelling cellular signalling systems. Essays Biochem 2008; 45:83-94; PMID:18793125; http://dx.doi.org/10.1042/bse0450083
99. H.Kitano. Computational systems biology. Nature 2002; 420:206-10; PMID:12432404; http://dx.doi.org/10.1038/nature01254
100. E.C.Butcher, E.L.Berg, E.J.Kunkel. Systems biology in drug discovery. Nat Biotechnol 2004; 22:1253-9; PMID:15470465; http://dx.doi.org/10.1038/nbt1017